The Genitourinary Steering Committee (GUSC) was established in 2008. At monthly meetings, the GUSC addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in genitourinary cancers. View the GUSC member roster. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Task Forces
- Task forces were established to discuss concepts and provide advisory input into concepts in each of the disease subtypes. View the GUSC Task Force member rosters:
- prostate
- bladder
- renal
Committee Highlights
The following are highlights from recent committee and task force activities:
- Combination Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
In December 2022, the Bladder Task Force held a CTPM that focused on defining the next generation of clinical trials with combination therapies to improve bladder preservation rates and survival outcomes for patients with high-risk, including BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC). Read the executive summary and publication in Bladder Cancer on advancing biomarker studies in NMIBC. - Small Renal Masses and Early Stage Renal Cell Carcinoma
In January 2020, the Renal Task Force held a CTPM that focused on improving the management of small renal masses and early-stage cell carcinoma cancer. Read the executive summary. - Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
In March 2015, the Bladder Task Force held a CTPM that focused on how to design clinical trials for non-muscle invasive bladder cancer using immunotherapy agents and targeted agents. Read the executive summary.
Contact
For more information, contact NCI CCCT Program Director, Abdul Tawab Amiri, Ph.D., at atawab@mail.nih.gov.